PatientsVille.com Logo


Heavy Medical Research Studies

Up-to-date List of Heavy Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Heavy Medical Research Studies

Rank Status Study
1 Unknown  Comparison of Standard and Minidose Spinal Anesthesia for Cesarean Section Operation Using Marcaine Spinal 0.5% Heavy
Conditions: Cesarean Section;   Anesthesia, Spinal;   Local Anaesthetics Causing Adverse Effects in Therapeutic Use
Interventions: Drug: Bupivacaine and Fentanyl;   Drug: Bupivacaine
Outcome Measures: prominence of motor blockade;   operative condition;   intraoperative hypotension;   need for postoperative pain medication;   general patient satisfaction
2 Not yet recruiting Therapy Trial to Determine the Safety and Efficacy of Heavy Ion Radiotherapy in Patients With Osteosarcoma
Condition: Osteosarcoma
Intervention: Radiation: Heavy ion radiotherapy (C12)
Outcome Measures: feasibility, toxicity (tox) measured by the CTC Criteria .Unacceptable:grade 4 tox. A rate of acute tox (≤ 3 months during/after RT) > grade 3 of ≤ 5% and a rate of late tox > grade 3 of ≤ 3% will be acceptable.;   tumor response (RECIST criteria), disease free survival, overall survival and description of FDG-PET characteristics before and after RT.
3 Recruiting Heavy Metal Exposure in Predicting Peripheral Neuropathy in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy
Conditions: Male Breast Cancer;   Neurotoxicity;   Peripheral Neuropathy;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Other: laboratory biomarker analysis;   Other: questionnaire administration
Outcome Measures: Level of Heavy metal in blood and urine;   Incidence of high grade neurotoxicity, defined as grade >= 3 peripheral neuropathy, graded according to CTCAE v. 4.0
4 Recruiting Reducing Heavy Drinking to Optimize HIV/AIDS Treatment and Prevention
Condition: Reduction in Heavy Drinking in Patients With HIV
Interventions: Drug: Naltrexone;   Other: Placebo + Medication Management/Medication Coaching
Outcome Measures: To compare the efficacy of NTX +MM/MC versus placebo +MM/MC on adherence to HAART.;   To compare the efficacy of NTX +MM/MC versus placebo +MM/MC in reducing days of Heavy drinking.
5 Recruiting Zonisamide for Heavy Drinkers With Bipolar Disorder
Conditions: Alcohol Use Disorders;   Bipolar Disorder
Interventions: Drug: Zonisamide;   Drug: Placebo
Outcome Measures: Percentage of total Heavy Drinking Days;   Change on Hamilton Depression Rating Scale;   Change in Clinician Assisted Rating Scale for Mania (CARS-M) Scores;   Percentage of Abstinent Days;   Change in Alcohol Urge Questionnaire Score;   Change in Gamma glutamyl transferase (GGT);   Change in Beck Depression Inventory (BDI) Scores;   Percentage of total drinking days;   Change in number of Heavy drinking days per week by time;   Change in number of drinks per week by time
6 Recruiting Dexmedetomidine in Spinal Anesthesia
Conditions: Blood Pressure;   Anxiety
Interventions: Drug: Dexmedetomidine;   Drug: Dexmedetomidine with Heavy bupivacaine
Outcome Measures: Hemodynamic effects;   Patient's comfortability and anxiety
7 Recruiting Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)
Conditions: Heavy Uterine Bleeding;   Uterine Fibroids
Interventions: Other: Placebo;   Drug: Elagolix;   Drug: Estradiol/norethindrone acetate, E2/NETA;   Drug: Estradiol/norethindrone acetate, E2/NETA Dose 2;   Drug: Estradiol/norethindrone acetate
Outcome Measures: Change in Menstrual Blood Loss;   Change in Physical Examination;   Change from Baseline in the number of subjects with adverse events;   Change in Bone Mineral Density (BMD);   Change in Endometrial Assessment;   Change in Clinical Laboratory Tests;   Percentage of Subjects with reduction in Menstrual Blood Loss;   Percentage Subjects with amenorrhea;   Percentage of Subjects with No Bleeding (spotting allowed);   Number of Bleeding Days;   Percent Change from baseline in bleeding scores per bleeding diary;   Percent Change in Uterine Volume;   Percent Change in Fibroid Volume;   Percent change in hemoglobin concentration;   Change in bone mineral density;   Change in percentage of subjects with hypoestrogenic effects;   Proportion reporting treatment-emergent adverse events;   Change from Baseline in the percent of subjects with adverse events
8 Recruiting New Approaches to Smoking Cessation in Heavy Drinkers
Conditions: Nicotine Dependence;   Cigarette Smoking;   Alcohol Consumption;   Heavy Drinking
Intervention: Drug: Varenicline
Outcome Measures: Evaluate feasibility and acceptability of cognitive-behavioral therapy (CBT) for smoking and alcohol (SA);   Smoking Abstinence;   Reductions in drinking
9 Recruiting Tranexamic Acid in Adolescents With Heavy Menstrual Bleeding
Condition: Heavy Menstrual Bleeding
Intervention: Drug: Tranxemic Acid
Outcome Measures: Quality of Life;   Menstrual blood loss, change in hemoglobin, and ferritin concentrations.
10 Unknown  Pretreatment With Norethindrone Acetate Prior to Levonorgestrel IUS Insertion for Heavy Menstrual Bleeding
Conditions: Heavy Menstrual Bleeding;   Menorrhagia;   Hypermenorrhea
Interventions: Drug: Norethindrone acetate pretreatment;   Other: No pretreatment
Outcome Measures: Total number of bleeding days;   Menorrhagia Questionnaire
11 Not yet recruiting A Web Application to Reduce Heavy Drinking in First-time DWI Offenders
Conditions: Driving While Intoxicated;   Driving Under the Influence;   Heavy Drinking;   Alcohol Abstinence
Interventions: Behavioral: Right Turns web application;   Behavioral: Treatment as usual
Outcome Measures: Quantity/frequency of alcohol use: Form 90;   Inventory of Drug Use Consequences (InDuC);   Self-efficacy
12 Not yet recruiting Topiramate's Effects on Heavy Drinking
Condition: Alcohol Drinking
Interventions: Drug: Topiramate;   Drug: Placebo
Outcome Measures: fMRI response in the ventral striatum/medial orbitofrontal cortex during alcohol cue exposure;   Drinking days;   change in gamma-glutamyl transferase (GGT) or carbohydrate-deficient transferrin (CDT) levels;   Heavy drinking days;   Mean alcohol consumption
13 Recruiting Estradiol vs Lysteda in Treatment of Heavy Menstrual Bleeding
Condition: Menstrual Cycle and Uterine Bleeding Disorders
Interventions: Drug: Estradiol;   Drug: Lysteda
Outcome Measures: menstrual blood loss;   changes in local hemostatic factors
14 Recruiting Study of a 4-phasic Oral Contraceptive for the Treatment of Heavy Menstrual Bleeding
Condition: Metrorrhagia
Interventions: Drug: EV/DNG (Qlaira, Natazia, BAY86-5027);   Drug: placebo
Outcome Measures: Absolute change in Menstrual Blood Loss (MBL) at baseline and 90 days;   Proportion of subjects with successful treatment;   Percent change of MBL at baseline and 90 day period during treatment phase;   Absolute change of average MBL at baseline and up to cycle 7 (one cycle = 28 days);   Proportion of subjects with improvement in the investigator's global assessment scale on Day 84;   Proportion of subjects with improvement in the investigator's global assessment scale on Day 196;   Proportion of subjects with improvement in the subject's global assessment scale on Day 84;   Proportion of subjects with improvement in the subject's global assessment scale on Day 196;   Number of participants with adverse events as a measure of safety and tolerability
15 Recruiting HMB- Data Collection Methods
Condition: Heavy Menstrual Bleeding
Interventions: Other: Web-based data collection;   Other: Paper-based data collection
Outcome Measures: Quality of Life;   Quality of data collected
16 Not yet recruiting Dexamethasone for Excessive Menstruation
Condition: Heavy Menstrual Bleeding
Interventions: Drug: Dexamethasone;   Drug: placebo
Outcome Measures: Change or difference in mean laboratory measured menstrual blood loss(MBL);   Menstrual diary score for volume of menstrual period;   Satisfaction with treatment by means of a participant completed treatment review questionnaire;   Number of participants with adverse events as a measure of safety and tolerability;   Examine effect of treatment on Period pain via participant self-report questionnaire;   Mechanistic examination of response to Dexamethasone
17 Recruiting Physical Activity as Intervention Against Age-related Loss of Muscle Mass and Function
Conditions: Muscle Weakness;   Muscle Loss;   Sarcopenia;   Physical Activity
Interventions: Procedure: Heavy resistance training;   Biological: Moderate intensity training;   Biological: Control;   Behavioral: Physical activity level
Outcome Measures: Change in leg extensor power;   Change in quadriceps cross sectional area;   Change in maximal isometric quadriceps strength;   Change in 30 s chair stand performance;   Change in 400 m gait speed;   Change in whole body composition and bone mineral density;   Change in grip strength;   Change in perceived age;   Change in blood parameters and anthropometry;   Change in physical activity level;   Change in Exercise self-efficacy;   Change in Health Related Quality of Life;   Changes in brain structure and function;   Change in cognitive ability;   Change in personality;   Change in mental symptoms
18 Recruiting Counteracting Age-related Loss of Skeletal Muscle Mass
Conditions: Sarcopenia;   Muscle Loss
Interventions: Procedure: Heavy Resistance Training;   Procedure: Light Intensity Training;   Dietary Supplement: Protein Whey;   Dietary Supplement: Protein Collagen;   Dietary Supplement: Carbohydrate
Outcome Measures: Change in muscle cross sectional area;   Change in quadriceps muscle isometric strength;   Change in quadriceps muscle isokinetic strength;   Change in leg extension muscle power;   Change from baseline in muscle structure and signalling;   Change in gut microbiota composition.;   Change in faecal metabolome.;   Change in plasma metabolome.;   Change in 30 s chair stand;   Change in whole body composition and bone mineral density
19 Recruiting Counteracting Age-related Loss of Skeletal Muscle Mass (CALM)
Conditions: Sarcopenia;   Muscle Loss
Interventions: Procedure: Heavy Resistance Training;   Procedure: Light Intensity Training;   Dietary Supplement: Protein Whey;   Dietary Supplement: Protein Collagen;   Dietary Supplement: Carbohydrate
Outcome Measures: 4 h basal muscle protein synthesis;   3 d muscle protein synthesis;   7 d muscle protein breakdown;   Muscle protein turnover molecular signaling and gene expression
20 Recruiting Stopping Heavy Periods Project
Conditions: Abnormal Uterine Bleeding;   Abnormal Uterine Bleeding, Ovulatory Dysfunction;   Abnormal Uterine Bleeding, Endometrial Hemostatic Dysfunction
Interventions: Device: Levonorgestrel intrauterine system;   Drug: Combined oral contraceptives
Outcome Measures: Menstrual Bleeding Questionnaire;   Treatment Failure

These studies may lead to new treatments and are adding insight into Heavy etiology and treatment.

A major focus of Heavy research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Heavy